The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70–90 years

Perminder S. Sachdev,[1,2,3] Henry Brodaty,[1,3,4] Simone Reppermund,[1]
Nicole A. Kochan,[1,2] Julian N. Trollor,[1,5] Brian Draper,[1,3,4] Melissa J. Slavin,[1]
John Crawford,[1] Kristan Kang,[1] G. Anthony Broe,[3,6,7] Karen A. Mather,[1,2]
Ora Lux[1,8] and the Memory and Ageing Study Team[1]

[1]*Brain and Ageing Research Program, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia*
[2]*Neuropsychiatric Institute, Prince of Wales Hospital, Barker Street, Randwick NSW 2031, Australia*
[3]*Primary Dementia Collaborative Research Centre, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia*
[4]*Academic Department for Old Age Psychiatry, Prince of Wales Hospital, Avoca Street, Randwick, NSW, Australia*
[5]*Intellectual Disability Mental Health, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia;*
[6]*Prince of Wales Medical Research Institute, Randwick NSW, Australia*
[7]*Ageing Research Centre, Prince of Wales Hospital, Barker Street, Randwick, NSW, Australia*
[8]*South Eastern Area Laboratory Service, Prince of Wales Hospital, Randwick, NSW, Australia*

ABSTRACT

Background: The Sydney Memory and Ageing Study (Sydney MAS) was initiated in 2005 to examine the clinical characteristics and prevalence of mild cognitive impairment (MCI) and related syndromes, and to determine the rate of change in cognitive function over time.

Methods: Non-demented community-dwelling individuals (N = 1037) aged 70–90 were recruited from two areas of Sydney, following a random approach to 8914 individuals on the electoral roll. They underwent detailed neuropsychiatric and medical assessments and donated a blood sample for clinical chemistry, proteomics and genomics. A knowledgeable informant was also interviewed. Structural MRI scans were performed on 554 individuals, and subgroups participated in studies of falls and balance, metabolic and inflammatory markers, functional MRI and prospective memory. The cohort is to be followed up with brief telephone reviews annually, and detailed assessments biannually.

Results: This is a generally well-functioning cohort mostly living in private homes and rating their health as being better than average, although vascular risk factors are common. Most (95.5%) participants or their informants identified a cognitive difficulty, and 43.5% had impairment on at least one neuropsychological test. MCI criteria were met by 34.8%; with19.3% qualifying for amnestic MCI, whereas 15.5% had non-amnestic MCI; 1.6% had impairment on neuropsychological test performance but no subjective complaints; and 5.8% could not be classified. The rate of MCI was 30.9% in the youngest (70–75) and 39.1% in the oldest (85–90) age bands. Rates of depression and anxiety were 7.1% and 6.9% respectively.

Conclusions: Cognitive complaints are common in the elderly, and nearly one in three meet criteria for MCI. Longitudinal follow-up of this cohort will delineate the progression of complaints and objective cognitive impairment, and the determinants of such change.

Key words: mild cognitive impairment, cognitive function, dementia, cognitive decline, magnetic resonance imaging (MRI), fMRI, metabolic syndrome, inflammatory markers, balance, falls, depression, anxiety, genetics, proteomics

Introduction

According to Australia's Health Report by the Australian Institute of Health and Welfare (AIHW, 2008), a baby born in Australia today can expect

to live for 81.4 years, with men expected to live for 79 years and women for almost 84 years – the second longest life expectancy in the world, after Japan. By the year 2030, the elderly (>65 years) in Australia will comprise 22% of the population, a quarter of whom will be over 80 (ABS, 1999). A conservative estimate is that 25% of this population will have significant neuropsychiatric syndromes (ABS, 1998) and in the very old (>85 years), the fastest growing age group in the population, the prevalence of neuropsychiatric syndromes could reach 80%. A major proportion of this neuropsychiatric disability is due to dementia. In Australia, there are currently about 230,000 people with dementia, and unless there is a significant medical breakthrough (Access Economics, 2006) this number is expected to rise to 731,000 by 2050. Direct health and residential care costs exceed $6.6 billion per annum, while the indirect costs in foregone earnings, carer time and expenses are many times this (Mathers *et al.*, 1999). By 2051, the impact of dementia will total 3.6% of GDP. The number of individuals with mild cognitive impairment (MCI) far exceeds the number with dementia, and the health impact of MCI is being increasingly appreciated. The challenge of the moment is to reduce disability among those currently affected and prevent disability among those at risk.

The field of neurocognitive disorders is in a state of flux. Basic neuroscience research is delineating the interaction of genetic predisposition, neurochemical changes, and comorbidity with diseases like cardiovascular disorders and diabetes in the genesis of neurocognitive syndromes (Ritchie and Lovestone, 2002). Evidence suggests there are overlapping neuropathologies and as a result the nosological boundaries of cognitive disorders are being re-examined. Dementia is a disorder which tends to have a gradual onset and a progressive course, and there is likely to be a variable and often prolonged period between the occurrence of the first features of cognitive impairment and the time when criteria for a dementia diagnosis are met. Various syndromes describing mild complaints of memory loss, or objectively determined memory/cognitive impairment or decline, have been proposed to represent this *predementia* period. These syndromes include age-associated memory impairment (AAMI), late-life forgetfulness (LLF), aging-associated cognitive decline (AACD), mild cognitive impairment (MCI), and cognitive impairment no dementia (CIND) (Ritchie and Touchon, 2000). There is considerable overlap between these syndromes conceptually and in practice (Ritchie *et al.*, 2001; Kumar *et al.*, 2005; Blossom *et al.*, 2007). Mild cognitive impairment (Winblad *et al.*, 2004) is currently the most

popular with researchers, although its veracity as a conceptual entity, diagnostic algorithm, and its ability to predict future dementia has been criticized (Mitchell *et al.*, 2008).

There is an international effort under way to better define the predementia syndromes and determine their predictive validity. It has been shown that patients with some MCI have a higher risk of progressing to Alzheimer's dementia (AD) than the general population over 65 years of age who convert at a rate of approximately 1–2% a year (Petersen *et al.*, 2001). Reported conversion rates differ depending on sample and diagnostic criteria, ranging between 3.7% and 25% annually (Ritchie *et al.*, 2001; Flicker *et al.*, 1991) although a median figure of about 12% conversion to dementia per year in MCI patients has been reported in clinic populations (Petersen, 2004). In community studies, the conversion rates are likely to be in the order of 6–10% (Petersen *et al.*, 2009).

The Sydney Memory and Ageing Study (MAS) was initiated in 2005 to complement the worldwide effort to study mild neurocognitive syndromes. The primary objective of the study is to examine the clinical characteristics and prevalence of MCI and related syndromes in non-demented older Australians, and to determine the rate of change in cognitive function over time. The expectation is that this approach would help determine the features of the syndrome that best predict decline towards a diagnosis of dementia, be it AD, vascular dementia (VaD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD) or mixed dementia. It is expected that there would possibly be a ten-fold variation in the prevalence of MCI depending upon the criteria being used. The study also purports to examine predictors of cognitive decline from sociodemographic, clinical, neuropsychological, neuroimaging, biochemical, genetics, and proteomics perspectives. A secondary objective is to assess behavioral and psychological symptoms in MCI. It is hypothesized that many of the participants, all non-demented at the time of recruitment, would have a transition into dementia during the course of the study. As a result, the study also offers the opportunity to examine the effects of entering into a care-giving role for the supporters of these individuals, which is a subsidiary objective. This paper describes the baseline medical and neuropsychiatric characteristics of the cohort, and in particular the prevalence rates of MCI and its sub-types.

Methods

Recruitment

Participants were recruited randomly through the electoral roll from two federal government areas of

Sydney, New South Wales, Australia – Kingsford-Smith and Wentworth. Registration on the electoral roll is compulsory in Australia, and this is a public document. Individuals in the age range 70–90 years on their last birthday were sent a letter inviting them to participate in the study. Those who responded in the affirmative were contacted by telephone to assess their eligibility. The cohort was recruited and examined for the first time (Wave 1) between September 2005 and November 2007, and this paper reports the results of this assessment.

Inclusion and exclusion criteria:

Participants aged 70–90 years living in the community were randomly selected to participate. They needed to speak and write English sufficiently well to complete a psychometric assessment and were able to consent to participate. The majority of participants (93.9%) had an informant who was the closest person to them and preferably someone who cohabitated with them. The informant had to know the participant well enough to be able to answer questions about the participant's memory, thinking, and daily functions.

The informant had to have at least weekly contact of not less than one hour with the participant.

Participants were excluded if they had a previous diagnosis of dementia, psychotic symptoms or a diagnosis of schizophrenia or bipolar disorder, multiple sclerosis, motor neuron disease, developmental disability, progressive malignancy (active cancer or receiving treatment for cancer, other than prostate – non-metastasized, and skin cancer), or if they had medical or psychological conditions that may have prevented them from completing assessments. Participants were excluded if they had a Mini-mental Statement Examination (MMSE; (Folstein *et al.*, 1975) score of <24 adjusted for age, education and non-English speaking background (Anderson *et al.*, 2007) at study entry, or if they received a diagnosis of dementia after comprehensive assessment.

Consent and feedback

Written informed consent was obtained from both participants and informants. Each participant was free to refuse a specific part of the assessment (such as blood sampling or MRI). Formal feedback from assessments was provided in written reports to the participants and their general practitioners. If tests revealed that the participant required immediate medical or psychiatric attention, they were contacted by telephone as was their general practitioner. The study was approved by the Ethics Committees of the University of New South Wales and the South Eastern Sydney and Illawarra Area Health Service.

Assessment

Consenting participants who met the inclusion criteria were assessed by trained research psychology graduates as follows:

Telephone Screen

This was performed prior to the face-to-face interview to confirm the following: willingness to participate, aged between 70 and 90 years, availability of an informant, adequate English language skills to complete a psychometric assessment (prompted with standardized questions), sufficient visual acuity to complete psychometric testing (with stimuli enlarged if necessary), and not meeting any exclusion criteria. It also collected demographic data (participant and informant) such as age, sex, education, marital status, occupation (current and previous), relationship between participant and informant, subjective cognitive complaints and the assessment of memory complaints in age-associated memory impairment (MAC-Q) (Crook *et al.*, 1992).

Face-to-Face Assessment

This was carried out in one or two sessions totaling three to four hours with appropriate breaks, and comprised a medical history interview and a neuropsychological and medical examination. The comprehensive neuropsychological battery was designed to assess various cognitive domains important for the diagnosis of dementia and predementia syndromes. The tests, and the associated domains, are detailed in Table 1.

The medical history interview included questions about vascular diseases and vascular risk factors (hypertension, hypercholesterolemia, history of dyslipidemia, atrial fibrillation, smoking, obesity, diabetes, stroke or transient ischemic attack, angina), cancer, alcohol and caffeine consumption, vitamin deficiency, thyroid disorders, head injury, chronic lung disease, arthritis, osteoporosis, migraines, kidney disease, urinary tract infections, exposure to pesticides, sleep habits, vision and hearing problems, mental health problems including depression and anxiety, and current medications. Symptoms of anxiety were assessed with the Goldberg Anxiety Scale (Goldberg *et al.*, 1988). We also collected information about health care utilization.

The medical examination comprised blood pressure (seated and standing), height and weight measures, hip to waist ratio, lateral stability test

Table 1. Neuropsychological test battery administered in the Sydney Memory and Ageing Study

COGNITIVE DOMAIN	TEST	NORMATIVE DATA SOURCE AND DEMOGRAPHIC ADJUSTMENTS
Premorbid intelligence	National Adult Reading Test (NART) (Nelson and Willison, 1991)	No adjustment (Nelson and Willison, 1991)
Attention/processing speed	Digit Symbol-Coding (Wechsler, 1997a)	Age (Wechsler, 1997a)
	Trail Making Test A (Reitan and Wolfson, 1993)	Age and education (Tombaugh, 2004)
Memory	Logical Memory Story A delayed recall (Wechsler, 1997b)	Education (Grundman *et al.*, 2004)
	Rey Auditory Verbal Learning Test (RAVLT) (Rey, 1964) RAVLT total learning; trials 1–5 RAVLT short-term delayed recall; trial 6 RAVLT long-term delayed recall; trial 7	Age (Harris *et al.*, 2002; Ivnik *et al.*, 1990; 1992a; 1992b)
	Benton Visual Retention Test recognition (Benton *et al.*, 1966)	Age and education (Lechevallier-Michel *et al.*, 2004)
Language	Boston Naming Test – 30 items (Kaplan *et al.*, 2001)	Age (Fastenau *et al.*, 1998)
	Semantic Fluency (Animals) (Spreen and Benton, 1969)	Age and education (Tombaugh *et al.*, 1999)
Visuo-spatial	Block Design (Weschler, 1981)	Age (Wechsler, 1981)
Executive function	Controlled Oral Word Association Test (FAS) (Benton, 1967)	Age and education (Tombaugh *et al.*, 1999)
	Trail Making Test B (Reitan and Wolfson, 1993)	Age and education (Tombaugh, 2004)
Fine motor	Grooved Pegboard Test (Klove, 1963)	No normative data

(Lord *et al.*, 1999), rigidity, rating of movement, speech, face and tremor, visual acuity, spirometry, grip strength, sit-to-stand test (Lord *et al.*, 2002), timed "up-and-go" test (Posiadlo and Richardson, 1991) and 6-meter timed walk (Waite *et al.*, 2001) and the Brief Smell Identification Test (B-SIT) (Doty *et al.*, 1996).

Participants were assessed at either a study center or in their own home if they were unable to visit the center. The assessment was split over two separate sessions if the participant was unable to do it in one session or if the assessment time exceeded four hours.

In addition to the in-person interview, participants were asked to complete the following self-report questionnaires: 15 item Geriatric Depression Scale (GDS; Yesavage *et al.*, 1983), Kessler 10 for psychological distress (K-10; Kessler and Mroczek, 1994), World Health Organization Disability Assessment Schedule II (WHODAS-II; Epping-Jordan and Üstün, 2000), Assessment of Quality of Life 2 (AQoL 2; Richardson *et al.*, 2004), current mental, social and physical activity, Food Frequency Questionnaire (Hodge *et al.*, 2000), family history, the positive scale of the Positive and Negative Affect Schedule (PANAS; Watson *et al.*, 1988), Satisfaction With Life Scale (SWLS; Diener *et al.*, 1985) and three subscales (neuroticism, openness and conscientiousness) of the NEO Five-Factor Inventory (Costa and McCrae, 1992).

Informant Interview and Questionnaires

Each participant's informant completed a phone interview and additional questionnaires as part of the caregiver component of the study. The phone interview was conducted by the same research psychologist who assessed the participant and it contained the Neuropsychiatric Inventory (NPI; Cummings *et al.*, 1994), Bayer Activities of Daily Living (B-ADL; Hindmarch *et al.*, 1998) and Instrumental Activities of Daily Living (IADL; Lawton and Brody, 1969). The Clinical Dementia Rating Scale (CDR; Morris, 1993) was administered to assess the severity of cognitive disorders. In addition, the informant completed a questionnaire about care provision, a sleep questionnaire, and a short informant questionnaire on cognitive decline in the elderly (IQCODE; Jorm, 1994). To examine the burden of the carer, the informant completed self-reported questionnaires relating to quality of life (AQoL 2; Richardson *et al.*, 2004), disability (WHODAS-II; Epping-Jordan and Utsun, 2000) and psychological distress (K-10; Kessler and Mroczek, 1994).

BLOOD TESTS

A blood sample was obtained after overnight fasting for the following investigations (not exclusively): full blood count, electrolytes, fasting blood glucose, lipid profile, C-reactive protein, vitamin B12, folate, thyroid stimulating hormone, homocysteine, total antioxidant capacity, malondialdehyde (MDA), vitamins A and E, carotene, EDTA plasma for proteomics, clotted blood for extraction of DNA, and buffy coat for cell lines.

MRI SCANS

All participants were invited to undergo a MRI scan, and those who agreed were screened for contraindications (pacemaker, metallic implant or foreign bodies, cochlear implants, ferromagnetic homeostatic clips, claustrophobia), and were then scanned using a Philips 3T Achieva Quasar Dual scanner (Philips Medical Systems, Best, The Netherlands) located at the Prince of Wales Medical Research Institute, Sydney. Our standard protocol was: (a) a scout mid-sagittal cut for AC-PC plane alignment; (b) 3D T1-weighted structural (T1w TFE – turbo field echo) MRI, acquired coronally with repetition time $TR = 6.39$ ms, echo time $TE = 2.9$ ms, flip angle $= 8°$, matrix size $= 256 \times 256$, field of view $FOV = 256 \times 256 \times 190$ mm^3, and slice thickness $=$ 1 mm with no gap between; yielding $1 \times 1 \times 1$ mm^3 isotropic voxels; (c) T2-weighted fluid attenuated inversion recovery (FLAIR) sequence, acquired coronally with $TR = 10000$ ms, $TE = 110$ ms, inversion time $TI = 2800$ ms; matrix size $= 512 \times 512$; slice thickness $= 3.5$ mm with no gap between slices, yielding spatial resolution of $0.488 \times 0.488 \times 3.5$ mm^3/voxel; and (d) diffusion weighted imaging (DWI) scans with a single-shot spin-echo echo-planar imaging (EPI) sequence, scanned axially with six directional diffusion-sensitizing gradients ($b = 1000$s/mm^2) with one no-diffusion-weighted $b = 0$ pulse; $TE = 68$ ms; flip angle $= 90°$; number of excitation (NEX) $= 1$; 38 axial slices with 3.5mm thickness and no gap; $FOV = 250 \times 133 \times 250$ mm^3, matrix size $= 128 \times 128$, in-plane image resolution $= 1.953 \times 1.953$mm. The total time of each subject's scanning session was approximately 20 minutes.

GENETICS AND GENOMICS

DNA was extracted from peripheral blood leukocytes or saliva samples at Genetics Repositories Australia (www.powmri.edu.au/GRA.htm) using standard procedures. As an initial analysis, apolipoprotein E (APOE) genotyping was undertaken. The two single nucleotide polymorphisms (rs7412 and rs429358), which distinguish between the three APOE alleles $\varepsilon2$, $\varepsilon3$ and $\varepsilon4$ were genotyped using Taqman assays (Applied Biosystems Inc. (ABI), Foster City, CA, U.S.A.). The validity of the genotyping was confirmed in a subsample by employing an alternate genotyping method that uses polymerase chain reaction amplification and restriction digest analysis (Hixson and Vernier, 1990). A genome-wide association study (GWAS) using the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, U.S.A.) is in progress.

PROTEOMICS

A number of studies using newer proteomics techniques on blood samples from this cohort are in progress, using both hypothesis-driven and discovery approaches.

Follow-up assessments

The baseline assessment will essentially be repeated at two-yearly intervals after the initial assessment, with repeat blood sampling and MRI scans occurring in Wave 2 (2-year assessment) but not Wave 3 (4-year assessment). In the intervening years, participants will be contacted by telephone for a brief assessment. The telephone interview will include an update of the social and demographic data of the participant and informant and the Telephone Interview for Cognitive Status (TICS) (Brandt *et al.*, 1988; de Jager *et al.*, 2003). The B-ADL (Hindmarsh *et al.*, 1998) and IADL (Lawton and Brody, 1969) will be completed by the informant.

Sub-studies

The Sydney Memory and Ageing Study sample is supporting other studies in subsamples of the cohort, including the following:

- *Balance and Falls Study*: examines the predictors of falling in the elderly (N = 500 in Wave 1; N = 531 in Wave 2).
- *Metabolic and Inflammatory Markers Study*: assesses additional metabolic and cardiovascular risk factors for cognitive impairment (N = 916 in Wave 1; N = 722 in Wave 2)
- *Prospective Memory Study*: a neuropsychological study with a focus on prospective memory (N = 120, only in Wave 1).
- *Functional MRI study*: examines changes in brain activity (blood oxygen level dependant response) in response to increased memory load in persons with mild cognitive impairment (MCI) and cognitively normal matched controls (N = 53).

Analyses

CONSENSUS CONFERENCES

Individuals who met the following criteria were brought to a fortnightly case conference to

decide on a diagnosis: a score of at least 1.5 standard deviations below published normative data on a memory and a non-memory measure, or on two non-memory measures, or reduced neuropsychological scores *and* a decline in activities of daily living based on an informant interview. Consensus diagnoses were made by an expert team comprising neuropsychiatrists, psychogeriatricians, and neuropsychologists on the basis of the available clinical, neuropsychological, laboratory and imaging data. If a participant met the criteria for diagnosis of possible dementia at baseline, he/she was excluded from the study. Dementia was diagnosed on the basis of DSM-IV criteria, and an etiological diagnosis was made depending on various sets of criteria for dementia syndromes.

Participants were diagnosed with MCI using the most recent international consensus criteria (Winblad *et al.*, 2004). A diagnosis of MCI was made if *all* of the following criteria were met: (a) complaint of decline in memory or other cognitive function which may be self- or informant-reported (memory complaint was required for amnestic MCI classifications, either memory or other cognitive complaint for non-amnestic classifications); (b) cognitive impairment on objective testing, i.e. not normal for age as determined by performance on at least one test measure 1.5 SDs or more *below* published normative values (or comparable standardized score provided in the normative source compared to age and/or education-matched samples); (c) not demented – participants did not have a pre-existing diagnosis of dementia on entry to the study, had an adjusted MMSE score of ≥24 and did not meet DSM-IV criteria for possible or probable dementia based on comprehensive clinical, cognitive and informant data gathered at assessment; (d) essentially normal function or minimal impairment in instrumental activities of daily living (IADLs) defined by a total average score <3.0 on the Bayer ADL Scale (Hindmarch *et al.*, 1998). This was later modified to take into account only impairment due to cognitive impairment; if there were physical reasons for functional impairment this was not held to indicate abnormal function. Four MCI subtypes (Petersen, 2004) were delineated according to cognitive impairment profiles – amnestic single domain (only memory domain impaired), amnestic multiple domain (memory plus at least one non-memory domain impaired), non-amnestic single domain (one non-memory domain impaired), and non-amnestic multiple domain (more than one non-memory domain impaired). The criterion for impaired domain was met if at least one of the measures from the domain was impaired. Cognitive domains, constituent test measures and normative data used for impairment classification are shown in Table 1

Participants were classified as cognitively normal if performance on all test measures was above the 6.68 percentile (−1.5 SDs) or equivalent score compared to normative published values, they were not demented (see criterion (c) above) and they had normal function or minimal impairment in IADLs defined by a total average score <3.0 on the Bayer ADL scale. Cognitive complaint was allowed.

MCI and cognitively normal classifications were only applied to participants from English-speaking backgrounds since the available normative data are based on predominantly English speakers. MCI subtypes were diagnosed on the basis of the International Consensus Criteria (Winblad *et al.*, 2004). Impairment in a cognitive domain was considered present if the individual performed below 1.5 SD of age and education corrected norms for a test in that domain. Activities of daily living were considered to be impaired if the Bayer ADL score was >3.0. General cognitive function was considered to be preserved if MMSE score was >23.

MRI ANALYSES

Images are de-identified, and then transferred to a computer server for storage. We use both Windows and Linux Workstations for our imaging data processes. Volumetric analyses and visual ratings of atrophy and white matter disease are undertaken at baseline and compared with those obtained at 2-year follow-up. Volumes of hippocampus, entorhinal cortex, parahippocampal gyrus and temporal neocortex are obtained using a standard tracing protocol already in use in our laboratory which utilizes the region of interest (ROI) tool in ANALYZE (Biomedical Imaging Resource, Mayo Clinic, Rochester, MN, U.S.A. 2009). Automated processes include segmentation of structural 3D T1-weighted scans into gray matter, white matter, cerebrospinal fluid (CSF) and intracranial volumes (ICV) using software packages such as SPM (http://www.fil.ion.ucl.ac.uk/spm/, Statistical Parametric Mapping, Wellcome Department of Imaging Neuroscience, London, U.K.), and the FMRIB's Software Library (FSL) (http://www.fmrib.ox.ac.uk/fsl, Oxford Centre for Functional Magnetic Resonance Imaging of the Brain, Oxford University, U.K.). Regional change in cortical thickness and gray matter volumes are examined using FreeSurfer (http://surfer.nmr.mgh.harvard.edu/, the Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital Boston, MA, U.S.A.). Automated white matter hyperintensity (WMH) detection and classification is performed using in-house software

(Wen and Sachdev, 2004; Wen *et al.*, 2009). We also examine the cortical surface indices and sulcal width (Liu *et al.*, 2010) and interregional cortical volume correlations using a brain network approach by applying graph theory.

STATISTICAL ANALYSES

Descriptive statistics were computed to characterize the cohort. Sex differences in the cohort were determined using the t-test for continuous variables and χ^2 test for categorical variables. Repeated measures analyses of variance, multiple regression, mixed-effects models and survival analyses are planned to examine cognitive decline, conversion to dementia and potential predictors of such change. Other analyses will be determined by the particular objective or hypothesis. Analyses reported in this paper were performed using SPSS v18 (SPSS Inc, Chicago IL, U.S.A., 2006).

Results

The sample

Of the 8914 individuals aged 70–90 years invited to participate, 7142 either did not respond to the letter or declined to participate; the remaining 1772 were contacted by telephone to confirm eligibility. From among these individuals, 735 were either ineligible or declined after further information about the study. The final sample comprised 1037 individuals who received detailed Wave 1 assessment documentation. Of these, 943 (90.9%) provided a blood sample, with the remaining giving a saliva sample for DNA extraction. MRI scans were performed on 544 (52.5%) individuals (Figure 1).

The sociodemographic characteristics of the sample are presented in Table 2. The mean age of the sample was 78.84 years, and 44.8% were men. They had a mean education (Crawford *et al.*, 1989) of 11.6 years, with men being more educated by a mean 1.27 years. Just over 30% of the participants were born in countries other than Australia or New Zealand, and 15.8% of the sample came from a non-English speaking background; however 94.1% used English as the primary language at home. Being non-demented individuals, 97.5% lived in private homes, either alone (46.9%) or with someone else (50.6%). Pets were owned by 17.6%. When asked about their "main occupation", approximately 60% of men and 30% of women had an occupational status equivalent to the Australian Bureau of Statistics (ABS, 2003) skill level 1, indicating a bachelor's degree or higher or 5 years of equivalent post-school experience. Only 156 (15%) were currently working in some capacity, the remaining being retired.

To examine the representativeness of the sample, we compared those who were invited but did not participate with those who did. The two groups did not differ on age and sex. Further, we compared the participants in the study on sociodemographic characteristics with census data for the same geographical area obtained from the Australian Bureau of Statistics (ABS, 2003). There was no difference in the sex ratio, and while the age distributions were comparable, the Sydney MAS sample had a relatively lower proportion of individuals in the 70–74 age group (26.0% v. 32.3%, p < 0.05) and higher in the 75–80 age group (34.8% v. 29.9%, p < 0.05). The proportions in the 80–84 (26.9% v. 24.2%) and 85–89 (12.3% v. 13.6%) were not different. More Sydney MAS participants lived in private homes (97.5% v. 92.1% in the ABS data, p < 0.05) and were more educated than the comparable group in the census data (30.4% with tertiary and 56.4% with secondary education cf. 10.1% and 42.2% respectively for the ABS data).

The participants who had an MRI scan (n = 544), when compared with those who did not, were slightly younger (mean age 78.4 vs. 79.3 years, p = 0.005) and had more years of education (mean 11.83 vs. 11.34 years, p = 0.027), but did not differ on sex, MMSE and adjusted IADL scores.

Health characteristics

Some of the morbidities of the sample are summarized in Table 3.

VASCULAR RISK FACTORS

Hypertension was the most common vascular risk factor, with 60.9% of the sample having been diagnosed with hypertension previously and 59% being currently on antihypertensive drugs. Men and women were equally likely to be diagnosed with hypertension, although men were slightly more likely to be taking medication. At the time of assessment, 24.1% had systolic BP > 160 mm Hg and 14.3% had diastolic BP > 95 mm Hg, with men more likely to be currently hypertensive. Using a systolic BP of 160 and diastolic BP of 95 mm Hg as cut-offs, and including those previously diagnosed, a total of 65.1% had definite hypertension. Another 17.4% had borderline hypertension, with mean current systolic BP between 140 and 160 or diastolic BP 90–95 mm Hg. It is noteworthy that while only 17.5% were normotensive on examination, 59.0% of the sample was being treated with antihypertensive drugs. However, 29.7% of those on antihypertensive medication still had high blood pressure at the time of measurement. Similarly, while the rate of previously diagnosed diabetes mellitus was 12.2%, a number of participants had

Figure 1. MAS flowchart.

high fasting blood glucose ($\geq$7 mmol/L) and this included those who had never been diagnosed. While men were more likely to be diabetic, high cholesterol levels were more common in women. Twenty-two percent of participants were judged to be obese (BMI > 30.0), with no sex differences. While 54.0% had smoked at some stage in their lives (men more often than women), only 7.2% had smoked in the last month, the latter being women more often than men (9.9% vs. 5.1%,

Table 2. The sociodemographic characteristics of the sample

CHARACTERISTIC	TOTAL n = 1037		MALES n = 465 (44.8%)		FEMALES n = 572 (55.2%)		STATISTICS	
	MEAN	SD	MEAN	SD	MEAN	SD	t	p
Age	78.84	4.82	78.76	4.70	78.90	4.92	−0.442	0.659
Education (yrs)	11.60	3.47	12.30	3.83	11.03	3.05	5.796	<0.001
	N	% of sample	N	% of sample	N	% of sample	χ^2	p
NESB[a]	164	15.81	82	17.63	82	14.34	2.096	0.148
English as primary language (at home)	976	94.12	435	93.55	541	94.58	0.493	0.482
English as preferred language	972	93.73	432	92.90	540	94.41	0.985	0.321
Region of birth								
Australia/NZ	724	69.82	302	64.95	422	73.78	24.640	<0.001
Europe/UK	238	22.95	115	24.78	123	21.47		
Asia/Middle East	40	3.86	27	5.82	13	2.27		
Africa	25	2.41	11	2.37	14	2.44		
America	10	0.96	10	2.16	0	0.00		
Occupation†								
ABS Skill Level 1	451	43.49	283	60.86	168	29.37	169.364	<0.001
ABS Skill Level 2	65	6.27	39	8.39	26	4.55		
ABS Skill Level 3	189	18.23	86	18.49	103	18.01		
ABS Skill Level 4	184	17.74	38	8.17	146	25.52		
ABS Skill Level 5	86	8.29	11	2.37	75	13.11		
Home duties and other	62	5.98	8	1.72	54	9.44		
Accommodation								
In community alone	486	46.87	141	30.32	345	60.31	99.171	<0.001
Community with others	525	50.63	312	67.10	213	37.20		
Hostel villa	12	1.16	6	1.29	6	1.05		
Retirement home	7	0.68	1	0.22	6	1.05		
Other	7	0.68	5	1.08	2	0.35		
Own a pet	183	17.65	78	16.77	105	18.36	0.442	0.506

[a]NESB = Non-English speaking background.

† = Occupations have been grouped by ABS (Australian Bureau of Statistics) Skill Level which uses terminology from the Australian Qualifications Framework (AQF), for full details of this classification system see McLennan (1997). ABS Skill Levels can be summarized as follows: Level 1: Bachelors degree or higher, or 5+ yrs experience; Level 2: AQF/Advanced Diploma, or 3+ yrs experience; Level 3: AQF Certificate III/IV, or 3+ yrs experience; Level 4: AQF Certificate II, or 1+ yrs experience; Level 5: Complete secondary education or AQF Certificate I.

p < 0.05). Past stroke was reported by 4% and transient ischemic attacks by 6.8%. Coronary artery disease was common, with myocardial infarction being reported by 11.6% and cardiac angina by 13%, both being more common in men. Atrial fibrillation had been diagnosed in 9.2% men and 4.8% women.

ALCOHOL USE
Only 12.5% were total abstainers in the last year, and 28.3% drank daily, with an additional 13.9% drinking 4–6 times a week. Men were more likely to drink alcohol than women (37.0% men vs. 21.2% women who drank daily). Of the total sample, 529 (51%) reported drinking more heavily in the past, with 53.5% of this group reporting a history of drinking on four or more occasions per week and

57.3% reporting a consumption of four or more drinks per day on the average.

OTHER DISORDERS
Of note, 54.5% had been diagnosed with arthritis, 13.7% with cancer other than skin cancer and 13.2% with thyroid disorder. For thyroid disease, women far outnumbered men. Less common disorders were Parkinson's disease in 1.2%, epilepsy in 0.7%, and autoimmune disorders in 1.9%. Sleep apnoea had been diagnosed in 5.6%, more often in men.

VISION AND HEARING
While visual problems are common in this age group, 90.3% of the participants in this study had self-reported adequate vision when corrected

Table 3. Physical health status of participants

	WHOLE SAMPLE	MALES	FEMALES	χ^2	p
Diabetes previously diagnosed	12.2%	16.9%	8.4%	17.309	<0.001
	(1035)	(462)	(573)		
Fasting glucose level					
≥10 mmol/L	1.4%	1.9%	1.0%	1.278	0.258
7.0–10 mmol/L	8.7%	12.1%	5.8%	11.800	0.001
5.6–7 mmol/L	45.7%	50.5%	41.6%	7.265	0.007
<5.6 mmol/L	44.2%	35.5%	51.6%	24.220	<0.001
	(930)	(428)	(502)		
Diabetes (composite)					
Definite	13.4%	18.2%	9.4%	15.727	<0.001
Borderline	3.4%	4.4%	2.5%	2.427	0.119
No diabetes	83.2%	77.5%	88.1%	19.083	<0.001
	(948)	(435)	(513)		
Hypertension (doctor diagnosis)	60.9%	58.3%	63.0%	2.408	0.121
	(1033)	(460)	(573)		
On antihypertensive drug	59.0%	62.5%	56.2%	4.213	0.040
	(1037)	(464)	(573)		
Systolic BP >160 mm Hg	24.1%	27.3%	21.5%	4.536	0.033
Diastolic BP >95 mm Hg	14.3%	17.0%	12.0%	5.135	0.023
	(1015)	(458)	(557)		
Hypertension (composite)					
definite	65.1%	67.9%	62.8%	2.864	0.091
borderline	17.4%	17.9%	17.0%	0.147	0.702
Normotensive	17.5%	14.2%	20.2%	6.276	0.012
	(1023)	(458)	(565)		
On hypolipidaemic drug	51.6%	56.5%	47.6%	7.989	0.005
	(1037)	(464)	(573)		
Cholesterol level					
≥6.5 mmol/L	5.5%	1.9%	8.5%	20.068	<0.001
5.5–6.5 mmol/L	17.3%	12.3%	21.5%	13.580	<0.001
<5.5 mmol/L	77.3%	85.8%	70.0%	33.099	<0.001
	(933)	(430)	(503)		
Triglycerides >1.7 mmol/L	9.2%	7.9%	10.3%	1.637	0.201
	(933)	(430)	(503)		
Body mass index (BMI) > 30	22.0%	22.5%	21.5%	0.138	0.710
	(1010)	(453)	(557)		

Note: Numbers in parentheses indicate size of sample for a particular variable, owing to some missing data.

with glasses; 8.4% had problems reading small fonts or in dim light; 0.7% could not read or watch television and 0.6% were functionally blind. There were no significant sex differences in visual acuity. Hearing was self-reported as adequate in 59.2%, mildly impaired in 40.3% and a serious problem in 0.6%. Men were more likely to have been recommended a hearing aid (40.9% vs. 29.8%, p < 0.001).

COGNITIVE PROFILE
The mean adjusted MMSE score (Anderson *et al.*, 2007) was 28.70 (SD 1.34) with women scoring only slightly higher than men (28.75 vs. 28.63, t = −1.428, p = 0.154) (Table 4). The informants reported decline in function of the participants over the previous five years, with the

mean IQCODE score being 3.1 (SD 0.31), with 52.6% scoring >3.0, the cut-off for significant decline. This was not significantly different in men and women. The participants were mostly independent in ADLs and IADLs, with only 44 (4.5%) being impaired on IADLs based on a score >3.0 on the Bayer-ADL scale. The percentages of individuals with an impaired performance on various neuropsychological tests, based on a score <1.5 SD on published normative data for the individual's age and education where available (see Table 1), are presented in Table 5. The proportion with impairment varied from 1.0% on the Digit-Symbol coding task (Wechsler, 1997b) to 22.1% on the Boston Naming Test (Kaplan *et al*, 2001). Women were less likely to be impaired on the verbal memory tests.

Table 4. Cognitive and functional status of the sample

| | | TOTAL | | MALES | | FEMALES | | | |
		MEAN (SD)	N	MEAN (SD)	N	MEAN (SD)	N	STATISTIC	p
Global cognitive function	[a]MMSE	28.70 (1.34)	1037	28.63 (1.36)	465	28.75 (1.33)	572	$t = -1.428$	0.154
	[b]IQ-CODE	3.10 (0.31)	938	3.09 (0.32)	426	3.10 (0.30)	512	$t = -0.612$	0.541
	% Impaired[†]	*52.56%*		*49.77%*		*54.88%*		$\chi^2 = 2.442$	
Daily activities and function	[c]IADLs	7.19 (0.80)	972	7.22 (0.92)	439	7.17 (0.67)	533	$t = 1.058$	0.290
	% Impaired[†]	*9.36%*		*10.48%*		*8.44%*		$\chi^2 = 1.175$	*(0.278)*
	[d]B-ADLs (unadjusted)	1.41(0.49)	971	1.54 (0.64)	431	1.48 (0.65)	540	$t = 1.392$	0.164
	% Impaired[†]	*4.53%*		*4.87%*		*4.26%*		$\chi^2 = 0.208$	*(0.648)*
	[e]WHODAS-II	18.30 (6.32)	994	17.91(5.85)	442	18.61(6.66)	552	$t = -1.756$	0.079

[a]Mini-mental State Examination (Folstein *et al.*, 1975).
[b]Informant Questionnaire on Cognitive Decline in the Elderly (Jorm, 1994).
[c]Instrumental Activites of Daily Living (Lawton and Brody, 1969).
[d]Bayer-Activities of Daily Living (Hindmarch, 1998).
[e]World Health Organization Disability Assessment Schedule II (Epping-Jordan and Ustun, 2000).
[†]Figures in these rows represent the number and percentage of people with impaired function as measured using the IQ-CODE, Instrumental ADL and Bayer ADL scales. Consequently, the relevant statistic for comparing between the sexes is the chi-square. Impairment was defined as: IQ-CODE >3, ADL >7, Bayer ADL ≥ 3.

Table 5. Percentage of sample classified as impaired on neurological tests based on published normative data. Because of missing data, the sample size for each test is given in parentheses

	WHOLE SAMPLE	MALES	FEMALES	χ^2	p
National Adult Reading Test (NART)	0.3% (865)	0.3% (373)	0.4% (492)	0.118	0.732
Digit-Symbol Coding Task	1.0% (1016)	1.8% (457)	0.4% (559)	5.005	0.025
Trail Making Test A	4.7% (1015)	5.9% (457)	3.8% (558)	2.565	0.109
Trail Making Test B	7.5% (948)	8.3% (421)	6.8% (527)	0.742	0.389
Rey Auditory Verbal Learning Test, total of trials 1 to 5	3.0% (1028)	4.8% (458)	1.6% (570)	9.028	0.003
Rey Auditory Verbal Learning Test, trial 6	5.2% (1026)	6.4% (456)	4.2% (570)	2.388	0.122
Rey Auditory Verbal Learning Test, trial 7	1.6% (1026)	2.2% (456)	1.1% (570)	2.146	0.143
Logical Memory, Immediate recall	15.1% (1037)	19.8% (464)	11.3% (573)	14.363	<0.001
Benton Visual Retention Test	6.4% (1027)	5.9% (460)	6.9% (567)	0.430	0.512
Boston Naming Test	22.1% (953)	19.7% (432)	24.2% (521)	2.785	0.095
Phonemic Fluency (FAS)	4.5% (1031)	5.4% (461)	3.7% (570)	1.808	0.179
Semantic Fluency (animals)	6.2% (1032)	7.8% (461)	4.9% (571)	3.702	0.054
Block Design Task	4.1% (1034)	3.7% (463)	4.4% (571)	0.328	0.567

PREVALENCE OF MCI

The prevalence of MCI using the international consensus criteria (Winblad *et al.*, 2004) was based on 827 participants with a complete neuropsychological dataset and who had English proficiency adequate for conversation acquired at <9 years of age (Table 6). Participants were considered to have "subjective cognitive complaints" if they identified that their memory or other cognitive functioning was poorer than what

Table 6. Categorization of cognitive status of participants achieved by consensus, taking into consideration subjective (participant or informant) report, neuropsychological text performance, and functional status based on independence in activities of daily living

DIAGNOSIS	SUBTYPE[1]	COMPLAINTS?	N	PREVALENCE RATE[2]
No impairment		No	21	2.5%
		Yes	440	53.2%
Mild cognitive impairment (MCI)[3]	aMCI	Yes	87	10.5%
	amdMCI		73	8.8%
	nMCI		106	12.8%
	nmdMCI		22	2.7%
	Total MCI		288	34.8%
Cognitive impairment without complaints		No	13	1.6%
Mild functional impairment but normal cognition		Yes	7	0.8%
Mild cognitive impairment[4] and functional impairment		Yes	10	1.2%
Unclassified[5]			48	5.8%

[1]Subtypes apply only to participants with impaired neuropsychology scores.
[2]Rates are based on a subsample of 827 participants with an English-speaking background and complete neuropsychological data.
[3]Based on Petersen (2004) criteria.
[4]Cognitive impairment insufficient to diagnose dementia, but individuals above the cut-off on IADL scores.
[5]Due to incomplete data.
aMCI = amnestic MCI; amdMCI = amnestic multidomain MCI; nMCI = non-amnestic MCI; nmdMCI = non-amnestic multidomain MCI.

it used to be, or they were having some lapses of memory, or their informants reported some decline from previous functioning. The endorsement of items on the MAC-Q by the participants or the IQCODE by the informants was regarded as "subjective" complaints. Using this broad approach, nearly all participants (95.5%) identified at least one subjective complaint. However, the majority of individuals (56.5%) did not have impairment on neuropsychological tests when age-appropriate norms were considered. Two hundred and eighty eight participants (34.8%) had both subjective complaints as well as some objective evidence of impairment in one or more domains of cognitive functioning, meeting the criteria for MCI. Of these cases, 55.5% had poor performance on memory tests (19.3% of all participants) qualifying for amnestic MCI, whereas 44.5% had non-amnestic MCI (15.5% of all participants). The prevalence rates for MCI by five-year age bands (70–75, 75–80, 80–85 and 85–90 years) were 30.9%, 35.0%, 37.3% and 39.1% respectively. There were a few individuals (1.6%) who had impairment on neuropsychological test performance but they or their informants did not report any problems with their cognitive functioning. There were seven (0.8%) individuals who reported cognitive problems but performed well on neuropsychological tests. Another ten (1.2%) had mild impairment of cognition on testing which was insufficient to diagnose dementia but their informants reported impairment in their IADLs. About 6% could not be classified owing to some missing or ambiguous data.

PSYCHIATRIC STATUS
One hundred and sixty-three participants (16.3%) had received a diagnosis of depression at some time in their lives (women 18.5% and men 13.6%, p < 0.036), and of these one-third had received treatment from a psychiatrist. Currently, 7.1% scored 6 or more on the Geriatric Depression scale, and 6.9% scored 5 or more on the Goldberg Anxiety Scale, with no sex differences.

APOE GENOTYPING
APOE genotyping was successfully performed for the majority of the available DNA samples (>99%). Of the 944 Caucasian participants with APOE data, the frequencies of the six APOE genotypes were 0.4% for $\varepsilon2/\varepsilon2$, 1.6% for $\varepsilon4/\varepsilon4$, 1.5% for $\varepsilon2/\varepsilon4$, 13.5% for $\varepsilon2/\varepsilon3$, 19.6% for $\varepsilon3/\varepsilon4$ and 63.5% for $\varepsilon3/\varepsilon3$. Frequencies of the APOE alleles and genotypes in Caucasians were similar to other reports (Henderson *et al.*, 1995; Farrer *et al.*, 1997; Jorm *et al.*, 2007). The allele frequencies for each APOE single nucleotide polymorphism in Caucasians were in Hardy-Weinberg equilibrium ($p > 0.05$).

SUBJECTIVE HEALTH
The majority of the participants rated their general health as being good (42.2%), very good (31.2%) or excellent (10.1%), with 14.9% rating it as fair and only 1.6% as poor, with no significant sex differences. Seven hundred and twenty five participants (72.8%) felt their health was better than other individuals their age.

Discussion

This paper describes the methodology and baseline characteristics of the Sydney Memory and Ageing Study. The medical and neuropsychiatric profile of a cohort of elderly individuals recruited into a longitudinal study of cognition and aging has been presented. This is a generally well-functioning cohort, mostly living in private homes and rating their general health as being better than average. The proportion living in private homes is not very different from that of elderly Australians in general. According to the Australian census of 2001 (ABS, 2003), 94.7% of men and 91.8% of women in the age group 75–84 years were living in private homes, with the percentages higher in younger and much lower in older individuals (68.0% and 68.1% respectively in the 85–94 age group). This must be compared with 95.7% in private homes in our sample, noting that we excluded individuals with a diagnosis or a positive screen for dementia, and these are individuals who agreed to participate in a longitudinal study requiring significant cognitive resources.

As would be expected in an elderly cohort, there is significant morbidity in this population. Hypertension was common, with 59% of the cohort currently on anti-hypertensive medication, out of 60.9% who had been diagnosed to be hypertensive by their doctor. However, on examination, 24.1% had systolic hypertension and 14.3% had diastolic hypertension. Untreated or under-treated hypertension is quite common in the Australian population. In the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (Briganti *et al.*, 2003) prevalence of untreated hypertension in the elderly ($\geq$65 years) was 20.8% (CI 15.6–26.0), and the majority of these individuals had had a blood pressure measurement in the previous 12 months. Our study further supports the contention that hypertension continues to be suboptimally treated in the elderly population.

While diabetes was previously diagnosed in 12.2%, some participants (11.1%) had raised fasting blood glucose levels ($\geq$7 mmol/L). The prevalence of obesity was high (22%), but that of current smoking was low (7.2%). Other common disorders were coronary artery disease, arthritis, cancer and thyroid disease. Vision and hearing are commonly affected in this age group, although aids sufficiently corrected these problems in the majority. However, sensory impairment is an important consideration for performance on neuropsychological tests, and must be taken into account during administration and interpretation.

Our findings may be compared with the baseline characteristics of another elderly Australian cohort, the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging (Ellis *et al.*, 2009), with the important difference being that the latter recruited individuals aged >60 years by advertisement in three groups: Alzheimer's disease (n = 211), MCI (n = 133) and healthy controls (n = 768). Rates of hypertension and diabetes were lower in the AIBL study, but co-morbid medical illness was common in both cohorts. APOE ε4 carrier frequency was lower in MAS (22.7%) compared to both the healthy control group (27%0 and the MCI group (51%) in the AIBL study.

Elderly individuals almost invariably notice some difficulties with their memory or other cognitive functioning when they compare themselves with younger individuals or with what they used to be able to do (Slavin *et al.*, 2010). In a few cases, the report of decline comes from an informant and not from the study participant. It is rare (3.4% in our study) for there not to be a complaint about cognition from some source at least. This does not mean, however, that participants are concerned about their memory or have objective evidence of impairment. Impaired performance on neuropsychological tests was present in 42.9%, and 33.4% were judged to meet the international consensus criteria for MCI (Winblad *et al.*, 2004). The prevalence rates reported in the literature are very variable, reflecting the methodological differences in the studies. Most studies have reported a prevalence between 12% and 18% in individuals 65 years and older. One of the largest population-based studies – the Canadian Health and Ageing study (Graham *et al.*, 1997) – reported cognitive impairment not dementia (CIND) to have a rate of 18%. The Religious Orders Study (Bennett *et al.*, 2002), which comprised volunteers, reported prevalence for MCI of 26.4%, and the Indianapolis Study of Health and Aging reported prevalence of 23.4% (Unverzagt *et al.*, 2001). It must be noted that our sample is in the 70–90 age range, and therefore somewhat older than the other studies, and prevalence rates of MCI do increase with age, as they did in our sample, from 30.9% in the youngest age band to 39.1% in the oldest. A study with an age range similar to our study is the Mayo Clinic Study of Aging (Roberts *et al.*, 2008) which is a population-based study of nearly 3000 participants, and reported a prevalence of MCI of 15% in the non-demented population. It is possible that the difference relates to the manner in which the definition of MCI was operationalized (Kochan *et al.*, 2010). We used a neuropsychological algorithm to define MCI. This method is very sensitive to the choice of tests and the cut-offs used (Ritchie *et al.*, 2001; Larrieu *et al.*, 2002). Overall, our rates of MCI are somewhat

higher than comparable reports in the literature, and we attribute this to methodological differences.

We found that nearly half of the MCI group in our sample had impaired performance on tests of memory, thereby qualifying for amnestic MCI, and about one in four had single domain aMCI. The other half had non-amnestic MCI, which was much more likely to be single domain. The rates of the subtypes of MCI have been very variable in different studies, reflecting the effect of choice of tests and algorithms. In the Mayo Clinic Study (Roberts *et al.*, 2008), the ratio of aMCI to naMCI was 2:1. In the Canadian Study of Health and Aging (Graham *et al.*, 1997), 5.3% had a circumscribed memory problem, akin to single domain aMCI. In the Cardiovascular Health Study (Lopez *et al.*, 2003), 6% had single domain aMCI and 16% multiple domain disturbances. The validity of the different criteria is best judged in terms of predictive ability of any set of criteria for decline toward dementia. It is interesting that we found a small proportion of participants (0.73%) who performed in the normative range on neuropsychological tests were impaired on functional measures due to cognitive deficits as judged by their informants.

The rates of psychiatric disorder in our sample are consistent with what has been reported in similar populations. The best comparison data are from the Australian National Mental Health and Well-being Survey, although the age band was different from our cohort. In Australians aged 65 and above in the Survey, the 12-month prevalence of any mood disorder was 2.7% and of any anxiety disorder was 4.4% (Trollor *et al.*, 2007). The rates in the current study are higher but they are based on a cut-off on a rating scale rather than a diagnostic interview schedule, and this may overestimate the extent of clinical depression. It is interesting that nearly 1 in 8 participants had been diagnosed with depression at some stage in their lives.

In spite of the above disorders reported by the participants, they generally rated their health as being good to excellent. Only 1.6% rated it as being poor. This may reflect the fact that most older individuals expect some physical and cognitive morbidity to be part of the aging process, and report their health in relation to other individuals their own age. It is also possible that our cohort, having agreed to be part of a longitudinal study, have a positive bias toward their health.

Our study has a number of limitations. First, only a proportion of potential participants finally agreed to participate in the study. In fact, an approach was made to nearly 9000 individuals to achieve an eventual sample of 1037. For reasons of confidentiality, we were unable to obtain the demographic characteristics or the reasons for refusal from those who declined to participate, except for age and sex, on which those who declined did not differ from those participating. Our sample cannot therefore be considered to be truly representative of the older population. It is more likely to represent older individuals who live in private homes and are independent in basic activities of daily living. It is not unusual for a sample such as this one to be better educated than the general population, as was the case in another Australian study, the PATH Through Life Study (Jorm *et al.*, 2004; 2007). Secondly, we excluded individuals with a diagnosis of dementia or an adjusted MMSE score <24, as the objective was to select a non-demented sample. The cohort is therefore likely to be higher functioning than a truly representative population. Thirdly, adequate knowledge of English was required to be able to complete the assessment. Therefore, only 5.9% of the sample used a language other than English as a primary language at home, while 15.8% came from a non-English speaking background. Since all assessments were in English, detailed neuropsychological profiles of the latter group must be received with caution because of lack of good normative data.

Conclusions

The Sydney Memory and Ageing Study is an epidemiologically acquired cohort of elderly individuals from Eastern Sydney, New South Wales, Australia, who have had extensive neuropsychiatric evaluations and are being followed up every two years. It offers an excellent opportunity to examine cognitive disorders longitudinally to determine their correlates, course and outcome. The study also presents an opportunity for national and international collaboration with other similar studies in an effort to detect cognitive disorders early and work toward their prevention.

Conflict of interest

None.

Description of authors' roles

PSS contributed to the study design, obtained research funds, provided supervision of data gathering and analysis, and prepared the first draft and final paper. HB contributed to the study design, obtained research funds, provided supervision of data gathering and analysis, and commented on drafts. SR provided supervision of data gathering and analysis,

and commented on drafts. NAK contributed to the study design, provided supervision of data gathering and analysis, and commented on drafts. JNT contributed to the study design, provided supervision of data gathering, and commented on drafts. MJS contributed to the study design, provided supervision of data gathering and analysis, and commented on drafts. JC and KJK contributed to data analysis, and commented on drafts. BD and GAB contributed to the study design, and commented on drafts. KM contributed to genetic testing and data analysis, and commented on drafts. OL contributed to blood tests, clinical chemistry and some data analysis and commented on drafts.

Sydney MAS Team: Allison Bowman, Kim Burns, Joula Dekker, Louise Dooley, Michele de Permentier, Sarah Fairjones, Therese French, Cathy Foster, Emma Nugent-Clearly-Fox, Chien Gooi, Evelyn Harvey, Sharpley Hsieh, Laura Hughes, Sarah Jacek, Mary Johnston, Samantha Meeth, Eveline Milne, Angharad Moir, Roslyn O'Grady, Kia Pfaeffli, Carine Pose, Laura Reuser, Zeeshan Shahnawaz, Amanda Sharpley, Claire Thompson, Wiebke Queisser, Sam Wong: Contributed to data acquisition.

Acknowledgments

References

ABS (1998). *Mental Health and Wellbeing: Profile of Adults, Australia, 1997.* Canberra: Australian Bureau of Statistics.

ABS (1999). *Older People, Australia: A Social Report.* Cat. No. 4109.0. Canberra: Australian Bureau of Statistics.

ABS (2003). *Ageing in Australia: Census of Population and Housing 2001.* Canberra: Australian Bureau of Statistics.

ABS (2006). *Census of Population and Housing.* Cat. No. 2914.0. Canberra: Australian Bureau of Statistics.

Access Economics (2006). *Dementia in the Asia Pacific Region: The Epidemic is Here.* Canberra: Alzheimer's Australia.

AIHW (2008). *Australia's Health 2008.* Canberra: Australian Institute of Health and Welfare. Available at www.aihw.gov.au/publications/index.cfm/title/10585.

Anderson, T. M., Sachdev, P. S., Brodaty, H., Trollor, J. N. and Andrews, G. (2007). Effects of sociodemographic and health variables on Mini-mental State Exam scores in older Australians. *American Journal of Geriatric Psychiatry*, 15, 467–476.

Bennett, D. A. *et al.* (2002). Natural history of mild cognitive impairment in older persons. *Neurology*, 59, 198–205.

Benton, A. L. (1967). Problems of test construction in the field of aphasia. *Cortex*, 3, 32–58.

Benton, A. L., Sivan, A. B. and Spreen, O. (1966). *Der Benton Test* (7th edn). Bern: Huber.

Blossom, C. *et al.* (2007). Early cognitive change in the general population: how do different definitions work? *Journal of the American Geriatrics Society*, 55, 1534–1540.

Brandt, J., Spencer, M. and Folstein, M. (1988). The telephone interview for cognitive status. *Neuropsychiatry, Neuropsychology, and Behavioral Neurology*, 1, 111–117.

Briganti, E. M. *et al.* (2003). Untreated hypertension among Australian adults: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). *Medical Journal of Australia*, 179, 135–139.

Costa, P. T. and McCrae, R. R. (1992). *NEO PI-R Professional Manual. Revised NEO Personality Inventory (NEO PI-R) and NEO Five-Factor Inventory (NEO-FFI).* Odessa: Psychological Assessment Resources Inc.

Crawford, J. R., Stewart, L. E., Cochrane, R. H. B., Foulds, J. A., Besson, J. A. O. and Parker, D. M. (1989). Estimating premorbid IQ from demographic variables: regression equations derived from a U.K. sample. *British Journal of Clinical Psychology*, 28, 275–278.

Crook, T. H., Feher, E. P. and Larrabee, G. J. (1992). Assessment of memory complaint in age-associated memory impairment: the MAC-Q. *International Psychogeriatrics*, 4, 165–175.

Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A. and Gornbein, J. (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. *Neurology*, 44, 2308–2314.

de Jager, C. A., Budge, M. M. and Clarke, R. (2003). Utility of TICS-M for the assessment of cognitive function in older adults. *International Journal of Geriatric Psychiatry*, 18, 318–324.

Diener, E., Emmons, R. A., Larsen, R. J. and Griffin, S. (1985). The Satisfaction With Life Scale. *Journal of Personality Assessment*, 49, 71–75.

Doty, R. L., Marcus, A. and Lee, W. W. (1996). Development of the 12-item cross-cultural Smell Identification Test™. *Laryngoscope*, 106, 353–356.

Ellis, K. A. *et al.* (2009). The Australian Imaging, Biomarkers and Lifestyle (AIB) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. *International Psychogeriatrics*, 21, 672–687.

Epping-Jordan, J. E. and Üstün, T. B. (2000). The WHODAS II: leveling the playing field for all disorders. *WHO Mental Health Bulletin*, 6, 5–6.

Farrer, L. A. *et al.* (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and

Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA*, 278, 1349–1356.

Fastenau, P. S., Denburg, N. L. and Mauer, B. A. (1998). Parallel short forms for the Boston Naming Test: psychometric properties and norms for older adults. *Journal of Clinical and Experimental Neuropsychology*, 20, 828–834.

Flicker, C., Ferris, S. H. and Reisberg, B. (1991). Mild cognitive impairment in the elderly: predictors of dementia. *Neurology*, 41, 1006–1009.

Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. *Journal of Psychiatric Research*, 12, 189–198.

Goldberg, D., Bridges, K., Duncan-Jones, P. and Grayson, D. (1988). Detecting anxiety and depression in general medical settings. *BMJ*, 297, 897–899.

Graham, J. E. *et al.* (1997) Prevalence and severity of cognitive impairment with and without dementia in an elderly population. *Lancet*, 349, 1793–1796.

Grundman, M. *et al.* (2004). Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. *Archives of Neurology*, 61, 59–66.

Harris, M. E., Ivnik, R. J. and Smith, G. E. (2002). Mayo's Older Americans Normative Studies: expanded AVLT Recognition Trial norms for ages 57 to 98. *Journal of Clinical and Experimental Neuropsychology*, 24, 214–220

Henderson, A. S. *et al.* (1995). Apolipoprotein E allele ε4, dementia, and cognitive decline in a population sample. *Lancet*, 346, 1387–1390.

Hindmarch, I., Lehfeld, H., de Jongh, P. and Erzigkeit, H. (1998). The Bayer Activities of Daily Living Scale (B-ADL). *Dementia and Geriatric Cognitive Disorders*, 9, 20–26.

Hixson, J. E. and Vernier, D. T. (1990). Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha1. *Journal of Lipid Research*, 31, 545–548.

Hodge, A., Patterson, A. J., Brown, W. J., Ireland, P. and Giles, G. (2000). The Anti Cancer Council of Victoria FFQ: relative validity of nutrient intakes compared with weighed food records in young to middle-aged women in a study of iron supplementation. *Australian and New Zealand Journal of Public Health*, 24, 576–583.

Ivnik, R. J., Malec, J. F., Tangalos, E. G., Petersen, R. C., Kokmen, E. and Kurland, L. T. (1990). The Auditory-Verbal Learning Test (AVLT): norms for ages 55 years and older. *Psychological Assessment*, 2, 304–312.

Ivnik, R. J. *et al.* (1992a). Mayo's Older Americans Normative Studies: updated AVLT norms for ages 56 to 97. *Clinical Neuropsychology*, 6, S83–S104.

Ivnik, R. J. *et al.* (1992b). Mayo's Older Americans Normative Studies: WAIS-R norms for ages 56 to 97. *Clinical Neuropsychology*, 6, S1–S30.

Jorm, A. F. (1994). A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. *Psychological Medicine*, 24, 145–153.

Jorm, A. F. *et al.* (2004). Memory complaints in a community sample aged 60–64 years: associations with cognitive functioning, psychiatric symptoms, medical

conditions, APOE genotype, hippocampus and amygdala volumes, and white matter hyperintensities. *Psychological Medicine*, 34, 1495–1506.

Jorm, A. F., Mather, K. A., Butterworth, P., Anstey, K. J., Christensen, H. and Easteal, S. (2007). APOE genotype and cognitive functioning in a large age-stratified population sample. *Neuropsychology*, 21, 1–8.

Kaplan, E., Goodglass, H. and Weintraub, S. (2001). *The Boston Naming Test.* Baltimore: Lippincott, Williams & Wilkins.

Kessler, R. and Mroczek, D. (1994). Final version of our Non-specific Psychological Distress Scale. Unpublished memo. Ann Arbor, MI: Survey Research Center of the Institute for Social Research, University of Michigan.

Klove, H. (1963). Clinical neuropsychology. In F. M. Forster (ed.), *The Medical Clinics of North America* (pp. 1647–1658). New York: Saunders.

Kochan, N. A. *et al.* (2010). Effect of different impairment criteria on prevalence of "objective" mild cognitive impairment in a community sample. *American Journal of Geriatric Psychiatry*. Epublished ahead of print, doi: 10.1097/JGP.0b013e3181d6b6a9

Kumar, R. *et al.* (2005). Prevalence of Mild Cognitive Impairment in 60- to 64-year-old community-dwelling individuals: the Personality and Total Health Through Life 60+ study. *Dementia and Geriatric Cognitive Disorders*, 19, 67–74.

Larrieu, S. *et al.* (2002). Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. *Neurology*, 59, 1594–1599.

Lawton, M. P. and Brody, E. M. (1969). Assessment of older people: self maintaining and instrumental activities of daily living. *Gerontologist*, 9, 179–186.

Lechevallier-Michel, N., Fabrigoule, C., Lafont, S., Letenneur, L. and Dartigues, J. (2004). Normes pour le MMSE, le test de rétention visuelle de Benton, le set test d'Isaacs (15s. et 60s), le sous-test des codes de la WAIS et le test barrage de Zazzo, enfunction de l'âge, du sese et du niveau d'études, chez les sujets âgés de 70 ans et plus: données de la chorte PAQUID. *Revue Neurologique*, 160, 1059–1070.

Liu, T. *et al.* (2010). The effects of age and sex on cortical sulci in the elderly. *Neuroimage*, 51, 19–27.

Lopez, O. L. *et al.* (2003). Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: Part 1. *Archives of Neurology*, 60, 1385–1389.

Lord, S. R., Rogers, M. W., Howland, A. and Fitzpatrick, R. (1999). Lateral stability, sensimotor function and falls in older people. *Journal of the American Geriatrics Society*, 47, 1077–1081.

Lord, S. R., Murray, S. M., Chapman, K., Munro, B. and Tiedemann, A. (2002). Sit-to-stand performance depends on sensation, speed, balance, and psychological status in addition to strength in older people. *Journals of Gerontology: Medical Sciences*, 57, M539–M543.

Mathers, C., Vos, T. and Stevenson, C. (1999). *The Burden of Disease and Injury in Australia.* Canberra: Australian Institute of Health and Welfare.

McLennan, W. (1997). *ASCO: Australian Standard Classification of Occupations* (2nd edn). Canberra: Australian Bureau of Statistics.

Mitchell, T., Woodward, M. and Hirose, Y. (2008). A survey of attitudes of clinicians towards the diagnosis and treatment of mild cognitive impairment in Australia and New Zealand. *International Psychogeriatrics*, 20, 77–85.

Morris, J. C. (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*, 43, 2412–2414.

Nelson, H. E. and Willison, J. (1991). *National Adult Reading Test (NART): Test Manual* (2nd edn). Windsor: NFER Nelson.

Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. *Journal of Internal Medicine*, 256, 183–194.

Petersen, R. C. *et al.* (2001). Current concepts in mild cognitive impairment. *Archives of Neurology*, 58, 1985–1002.

Petersen, R. C. *et al.* (2009) Mild cognitive impairment: ten years later. *Archives of Neurology*, 66, 1447–1455.

Posiadlo, D. and Richardson, S. (1991). The timed "up and go": a test of basic functional mobility for frail elderly persons. *Journal of the American Geriatrics Society*, 39, 142–148.

Reitan, R. M. and Wolfson, D. (1993). *The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation* (2nd edn). Tucson, AZ: Neuropsychology Press.

Rey, A. (1964). *L'Examen Clinique en Psychologie*. Paris: Presses Universitaires de France.

Richardson, J., Day, N., Peacock, S. and Iezzi, A. (2004). Measurement of the quality of life for economic evaluation and the Assessment of Quality of Life (AQoL) Mark 2 instrument. *Australian Economic Review*, 37, 62–88.

Ritchie, K. and Lovestone, S. (2002). The dementias. *Lancet*, 360, 1759–1766.

Ritchie, K. and Touchon, J. (2000). Mild cognitive impairment: conceptual basis and current nosological status. *Lancet*, 355, 225–228.

Ritchie, K., Artero, S. and Touchon, J. (2001). Classification criteria for mild cognitive impairment: a population-based validation study. *Neurology*, 56, 37–42.

Roberts, R. O. *et al.* (2008). The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. *Neuroepidemiology*, 30, 58–68.

Slavin, M. J. *et al.* (2010). Prevalence and predictors of subjective cognitive complaints in the Sydney Memory and Ageing Study. *Americal Journal of Geriatric Psychiatry*. Published ahead of print, doi: 10.1097/JGP.0b013e3181df49fb

Spreen, O. and Benton, A. L. (1969). *Neurosensory Centre Comprehensive Examination for Aphasia Manual (NCCEA)*. Victoria: University of Victoria.

Tombaugh, T. N. (2004). Trail making test A and B: Normative data stratified by age and education. *Archives of Clinical Neuropsychology* 19, 203–214.

Tombaugh, T. N., Kozak, J. and Rees, L. (1999). Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. *Archives of Clinical Neuropsychology*, 14, 167–177.

Trollor, J., Anderson, T., Sachdev, P., Brodaty, H. and Andrews, G. (2007). Prevalence of mental disorders in the elderly: the Australian National Mental and Well-being Survey. *American Journal of Geriatric Psychiatry*, 15, 455–466.

Unverzagt, F. W. *et al.* (2001). Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging. *Neurology*, 57, 1655–1662.

Waite, L. M., Broe, G. A., Garyson, D. A. and Creasey, H. (2001). Preclinical syndromes predict dementia: the Sydney older persons study. *Journal of Neurology, Neurosurgery and Psychiatry*, 71, 296–302.

Watson, D., Clark, L. A. and Tellegen, A. (1988). Development and validation of brief measures of positive and negative affect: the PANAS Scales. *Journal of Personality and Social Psychology*, 54, 1063–1070.

Wechsler, D. (1981). *WAIS-R Manual*. Ner York: The Psychological Corporation.

Wechsler, D. (1997a). *Wechsler Adult Intelligence Scale-III*. San Antonio: The Psychological Corporation.

Wechsler, D. (1997b). *Wechsler Adult Intelligence Scale- 3rd Edition (WAIS-3®)*. San Antonio: Harcourt Assessment.

Winblad, B. *et al.* (2004). Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. *Journal of Internal Medicine*, 256, 240–246.

Wen, W. and Sachdev, P. S. (2004). Extent and distribution of white matter hyperintensities in stroke patients: the Sydney Stroke Study. *Stroke*, 35, 2813–2819.

Wen, W., Sachdev, P. S., Li, J. J., Chen, X. and Anstey, K. J. (2009). White matter hyperintensities in the forties: their prevalence and topography in an epidemiological sample aged 44–48. *Human Brain Mapping*, 30, 1155–1167.

Yesavage, J. A. *et al.* (1983). Development and validation of a geriatric depression rating scale: a preliminary report. *Journal of Psychatric Research*, 17, 37–49.